世界の二次性進行性多発性硬化症薬市場 2019年

【英語タイトル】Global Secondary Progressive Multiple Sclerosis Drug Market Professional Survey Report 2019

QYResearchが出版した調査資料(DATA909X14808)・商品コード:DATA909X14808
・発行会社(調査会社):QYResearch
・発行日:2019年11月20日(※2024年版があります。お問い合わせください)
・ページ数:111
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医薬品・ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥518,000見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,250 ⇒換算¥777,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,000 ⇒換算¥1,036,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
※本調査レポートは、二次性進行性多発性硬化症薬の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、イネビリズマブ、GLX-1112、DC-TAB、エトモキシル、IB-MS、その他に、用途別には、病院、診療所、その他にセグメント区分し、二次性進行性多発性硬化症薬の世界市場を分析しました。


・エグゼクティブ・サマリー
・二次性進行性多発性硬化症薬の世界市場概要
・二次性進行性多発性硬化症薬の製造コスト構成分析
・二次性進行性多発性硬化症薬の開発・製造工場分析
・主要メーカーの主な指標(生産能力、売上、価格分析)
・二次性進行性多発性硬化症薬の地域別分析(生産、売上、主要メーカー、輸出・輸入)
(北米、ヨーロッパ、中国、日本国内、東南アジア、インド)
・二次性進行性多発性硬化症薬のセグメント分析(種類別)
(イネビリズマブ、GLX-1112、DC-TAB、エトモキシル、IB-MS、その他)
・二次性進行性多発性硬化症薬のセグメント分析(用途別)
(病院、診療所、その他)
・二次性進行性多発性硬化症薬の主要メーカー別分析(生産拠点、製品概要、生産・売上実績)
(AB Science SA、Actelion Ltd、Biogen, Inc.、F. Hoffmann-La Roche Ltd.、Genzyme Corporation、Glialogix, Inc.、Immune Response BioPharma, Inc.、Innate Immunotherapeutics Ltd、Kyorin Pharmaceutical Co., Ltd.、Mallinckrodt Plc、MedDay SA、MedImmune, LLC、Merck KGaA、Meta-IQ ApS、Novartis AG、Opexa Therapeutics, Inc.、Xenetic Biosciences (UK) Limited、)
・二次性進行性多発性硬化症薬の市場規模予測(2019年~2025年)
(北米、ヨーロッパ、中国、日本国内、東南アジア、インド)
・マーケティングチャネル・流通業者・顧客
・市場ダイナミクス(市場動向、機会、成長要因、課題、影響因子)
...
【レポートの概要】

The global Secondary Progressive Multiple Sclerosis Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
This report focuses on Secondary Progressive Multiple Sclerosis Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Secondary Progressive Multiple Sclerosis Drug market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Secondary Progressive Multiple Sclerosis Drug in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Secondary Progressive Multiple Sclerosis Drug manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
AB Science SA
Actelion Ltd
Biogen, Inc.
F. Hoffmann-La Roche Ltd.
Genzyme Corporation
Glialogix, Inc.
Immune Response BioPharma, Inc.
Innate Immunotherapeutics Ltd
Kyorin Pharmaceutical Co., Ltd.
Mallinckrodt Plc
MedDay SA
MedImmune, LLC
Merck KGaA
Meta-IQ ApS
Novartis AG
Opexa Therapeutics, Inc.
Xenetic Biosciences (UK) Limited

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Inebilizumab
GLX-1112
DC-TAB
Etomoxir
IB-MS
Others

Segment by Application
Hospital
Clinic
Others

【レポートの目次】

Table of Contents

Executive Summary
1 Industry Overview of Secondary Progressive Multiple Sclerosis Drug
1.1 Definition of Secondary Progressive Multiple Sclerosis Drug
1.2 Secondary Progressive Multiple Sclerosis Drug Segment by Type
1.2.1 Global Secondary Progressive Multiple Sclerosis Drug Production Growth Rate Comparison by Types (2014-2025)
1.2.2 Inebilizumab
1.2.3 GLX-1112
1.2.4 DC-TAB
1.2.5 Etomoxir
1.2.6 IB-MS
1.2.7 Others
1.3 Secondary Progressive Multiple Sclerosis Drug Segment by Applications
1.3.1 Global Secondary Progressive Multiple Sclerosis Drug Consumption Comparison by Applications (2014-2025)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Secondary Progressive Multiple Sclerosis Drug Overall Market
1.4.1 Global Secondary Progressive Multiple Sclerosis Drug Revenue (2014-2025)
1.4.2 Global Secondary Progressive Multiple Sclerosis Drug Production (2014-2025)
1.4.3 North America Secondary Progressive Multiple Sclerosis Drug Status and Prospect (2014-2025)
1.4.4 Europe Secondary Progressive Multiple Sclerosis Drug Status and Prospect (2014-2025)
1.4.5 China Secondary Progressive Multiple Sclerosis Drug Status and Prospect (2014-2025)
1.4.6 Japan Secondary Progressive Multiple Sclerosis Drug Status and Prospect (2014-2025)
1.4.7 Southeast Asia Secondary Progressive Multiple Sclerosis Drug Status and Prospect (2014-2025)
1.4.8 India Secondary Progressive Multiple Sclerosis Drug Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Secondary Progressive Multiple Sclerosis Drug
2.3 Manufacturing Process Analysis of Secondary Progressive Multiple Sclerosis Drug
2.4 Industry Chain Structure of Secondary Progressive Multiple Sclerosis Drug

3 Development and Manufacturing Plants Analysis of Secondary Progressive Multiple Sclerosis Drug
3.1 Capacity and Commercial Production Date
3.2 Global Secondary Progressive Multiple Sclerosis Drug Manufacturing Plants Distribution
3.3 Major Manufacturers Technology Source and Market Position of Secondary Progressive Multiple Sclerosis Drug
3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers
4.1 Secondary Progressive Multiple Sclerosis Drug Production and Capacity Analysis
4.2 Secondary Progressive Multiple Sclerosis Drug Revenue Analysis
4.3 Secondary Progressive Multiple Sclerosis Drug Price Analysis
4.4 Market Concentration Degree

5 Secondary Progressive Multiple Sclerosis Drug Regional Market Analysis
5.1 Secondary Progressive Multiple Sclerosis Drug Production by Regions
5.1.1 Global Secondary Progressive Multiple Sclerosis Drug Production by Regions
5.1.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Regions
5.2 Secondary Progressive Multiple Sclerosis Drug Consumption by Regions
5.3 North America Secondary Progressive Multiple Sclerosis Drug Market Analysis
5.3.1 North America Secondary Progressive Multiple Sclerosis Drug Production
5.3.2 North America Secondary Progressive Multiple Sclerosis Drug Revenue
5.3.3 Key Manufacturers in North America
5.3.4 North America Secondary Progressive Multiple Sclerosis Drug Import and Export
5.4 Europe Secondary Progressive Multiple Sclerosis Drug Market Analysis
5.4.1 Europe Secondary Progressive Multiple Sclerosis Drug Production
5.4.2 Europe Secondary Progressive Multiple Sclerosis Drug Revenue
5.4.3 Key Manufacturers in Europe
5.4.4 Europe Secondary Progressive Multiple Sclerosis Drug Import and Export
5.5 China Secondary Progressive Multiple Sclerosis Drug Market Analysis
5.5.1 China Secondary Progressive Multiple Sclerosis Drug Production
5.5.2 China Secondary Progressive Multiple Sclerosis Drug Revenue
5.5.3 Key Manufacturers in China
5.5.4 China Secondary Progressive Multiple Sclerosis Drug Import and Export
5.6 Japan Secondary Progressive Multiple Sclerosis Drug Market Analysis
5.6.1 Japan Secondary Progressive Multiple Sclerosis Drug Production
5.6.2 Japan Secondary Progressive Multiple Sclerosis Drug Revenue
5.6.3 Key Manufacturers in Japan
5.6.4 Japan Secondary Progressive Multiple Sclerosis Drug Import and Export
5.7 Southeast Asia Secondary Progressive Multiple Sclerosis Drug Market Analysis
5.7.1 Southeast Asia Secondary Progressive Multiple Sclerosis Drug Production
5.7.2 Southeast Asia Secondary Progressive Multiple Sclerosis Drug Revenue
5.7.3 Key Manufacturers in Southeast Asia
5.7.4 Southeast Asia Secondary Progressive Multiple Sclerosis Drug Import and Export
5.8 India Secondary Progressive Multiple Sclerosis Drug Market Analysis
5.8.1 India Secondary Progressive Multiple Sclerosis Drug Production
5.8.2 India Secondary Progressive Multiple Sclerosis Drug Revenue
5.8.3 Key Manufacturers in India
5.8.4 India Secondary Progressive Multiple Sclerosis Drug Import and Export

6 Secondary Progressive Multiple Sclerosis Drug Segment Market Analysis (by Type)
6.1 Global Secondary Progressive Multiple Sclerosis Drug Production by Type
6.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Type
6.3 Secondary Progressive Multiple Sclerosis Drug Price by Type

7 Secondary Progressive Multiple Sclerosis Drug Segment Market Analysis (by Application)
7.1 Global Secondary Progressive Multiple Sclerosis Drug Consumption by Application
7.2 Global Secondary Progressive Multiple Sclerosis Drug Consumption Market Share by Application (2014-2019)

8 Secondary Progressive Multiple Sclerosis Drug Major Manufacturers Analysis
8.1 AB Science SA
8.1.1 AB Science SA Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
8.1.2 AB Science SA Product Introduction, Application and Specification
8.1.3 AB Science SA Secondary Progressive Multiple Sclerosis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.1.4 Main Business and Markets Served
8.2 Actelion Ltd
8.2.1 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
8.2.2 Actelion Ltd Product Introduction, Application and Specification
8.2.3 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.2.4 Main Business and Markets Served
8.3 Biogen, Inc.
8.3.1 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
8.3.2 Biogen, Inc. Product Introduction, Application and Specification
8.3.3 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.3.4 Main Business and Markets Served
8.4 F. Hoffmann-La Roche Ltd.
8.4.1 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
8.4.2 F. Hoffmann-La Roche Ltd. Product Introduction, Application and Specification
8.4.3 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.4.4 Main Business and Markets Served
8.5 Genzyme Corporation
8.5.1 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
8.5.2 Genzyme Corporation Product Introduction, Application and Specification
8.5.3 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.5.4 Main Business and Markets Served
8.6 Glialogix, Inc.
8.6.1 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
8.6.2 Glialogix, Inc. Product Introduction, Application and Specification
8.6.3 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.6.4 Main Business and Markets Served
8.7 Immune Response BioPharma, Inc.
8.7.1 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
8.7.2 Immune Response BioPharma, Inc. Product Introduction, Application and Specification
8.7.3 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.7.4 Main Business and Markets Served
8.8 Innate Immunotherapeutics Ltd
8.8.1 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
8.8.2 Innate Immunotherapeutics Ltd Product Introduction, Application and Specification
8.8.3 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.8.4 Main Business and Markets Served
8.9 Kyorin Pharmaceutical Co., Ltd.
8.9.1 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
8.9.2 Kyorin Pharmaceutical Co., Ltd. Product Introduction, Application and Specification
8.9.3 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.9.4 Main Business and Markets Served
8.10 Mallinckrodt Plc
8.10.1 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
8.10.2 Mallinckrodt Plc Product Introduction, Application and Specification
8.10.3 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.10.4 Main Business and Markets Served
8.11 MedDay SA
8.12 MedImmune, LLC
8.13 Merck KGaA
8.14 Meta-IQ ApS
8.15 Novartis AG
8.16 Opexa Therapeutics, Inc.
8.17 Xenetic Biosciences (UK) Limited

9 Development Trend of Analysis of Secondary Progressive Multiple Sclerosis Drug Market
9.1 Global Secondary Progressive Multiple Sclerosis Drug Market Trend Analysis
9.1.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size (Volume and Value) Forecast 2019-2025
9.2 Secondary Progressive Multiple Sclerosis Drug Regional Market Trend
9.2.1 North America Secondary Progressive Multiple Sclerosis Drug Forecast 2019-2025
9.2.2 Europe Secondary Progressive Multiple Sclerosis Drug Forecast 2019-2025
9.2.3 China Secondary Progressive Multiple Sclerosis Drug Forecast 2019-2025
9.2.4 Japan Secondary Progressive Multiple Sclerosis Drug Forecast 2019-2025
9.2.5 Southeast Asia Secondary Progressive Multiple Sclerosis Drug Forecast 2019-2025
9.2.6 India Secondary Progressive Multiple Sclerosis Drug Forecast 2019-2025
9.3 Secondary Progressive Multiple Sclerosis Drug Market Trend (Product Type)
9.4 Secondary Progressive Multiple Sclerosis Drug Market Trend (Application)

10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.3 Secondary Progressive Multiple Sclerosis Drug Customers

11 Market Dynamics
11.1 Market Trends
11.2 Opportunities
11.3 Market Drivers
11.4 Challenges
11.5 Influence Factors

12 Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Author List
13.4 Disclaimer

List of Tables and Figures
Figure Picture of Secondary Progressive Multiple Sclerosis Drug
Table Global Secondary Progressive Multiple Sclerosis Drug Production (K Pcs) Growth Rate Comparison by Types (2014-2025)
Figure Global Secondary Progressive Multiple Sclerosis Drug Production Market Share by Types in 2018
Figure Inebilizumab Product Picture
Figure GLX-1112 Product Picture
Figure DC-TAB Product Picture
Figure Etomoxir Product Picture
Figure IB-MS Product Picture
Figure Others Product Picture
Table Global Secondary Progressive Multiple Sclerosis Drug Consumption (K Pcs) Comparison by Applications (2014-2025)
Figure Global Secondary Progressive Multiple Sclerosis Drug Consumption Market Share by Applications in 2018
Figure Hospital
Figure Clinic
Figure Others
Figure Global Secondary Progressive Multiple Sclerosis Drug Revenue (Million USD) (2014-2025)
Figure Global Secondary Progressive Multiple Sclerosis Drug Production (K Pcs) (2014-2025)
Figure North America Secondary Progressive Multiple Sclerosis Drug Market Size (Million USD) (2014-2025)
Figure Europe Secondary Progressive Multiple Sclerosis Drug Market Size (Million USD) (2014-2025)
Figure China Secondary Progressive Multiple Sclerosis Drug Market Size (Million USD) (2014-2025)
Figure Japan Secondary Progressive Multiple Sclerosis Drug Market Size (Million USD) (2014-2025)
Figure Southeast Asia Secondary Progressive Multiple Sclerosis Drug Market Size (Million USD) (2014-2025)
Figure India Secondary Progressive Multiple Sclerosis Drug Market Size (Million USD) (2014-2025)
Table Secondary Progressive Multiple Sclerosis Drug Raw Material and Suppliers
Table Manufacturing Cost Structure Analysis of Secondary Progressive Multiple Sclerosis Drug in 2018
Figure Manufacturing Process Analysis of Secondary Progressive Multiple Sclerosis Drug
Figure Industry Chain Structure of Secondary Progressive Multiple Sclerosis Drug
Table Capacity and Commercial Production Date of Key Manufacturers
Table Global Secondary Progressive Multiple Sclerosis Drug Manufacturing Plants Distribution
Table Secondary Progressive Multiple Sclerosis Drug Major Manufacturers Technology Source and Market Position
Table Recent Development and Expansion Plans in Future
Table Secondary Progressive Multiple Sclerosis Drug Capacity (K Pcs) of Major Manufacturers (2014-2019)
Table Secondary Progressive Multiple Sclerosis Drug Production (K Pcs) of Major Manufacturers (2014-2019)
Table Secondary Progressive Multiple Sclerosis Drug Production Market Share of Major Manufacturers (2014-2019)
Figure Secondary Progressive Multiple Sclerosis Drug Production Share by Manufacturers in 2018
Table Secondary Progressive Multiple Sclerosis Drug Revenue (Million US$) of Major Manufacturers (2014-2019)
Table Secondary Progressive Multiple Sclerosis Drug Revenue Market Share of Major Manufacturers (2014-2019)
Figure Secondary Progressive Multiple Sclerosis Drug Revenue Share by Manufacturers in 2018
Table Secondary Progressive Multiple Sclerosis Drug Average Price (USD/Pcs) of Major Manufacturers (2014-2019)
Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Global Secondary Progressive Multiple Sclerosis Drug Production by Regions 2014-2019 (K Pcs)
Table Global Secondary Progressive Multiple Sclerosis Drug Production Market Share by Regions 2014-2019
Figure Global Secondary Progressive Multiple Sclerosis Drug Production Market Share by Regions in 2018
Table Global Secondary Progressive Multiple Sclerosis Drug Revenue by Regions 2014-2019 (Million USD)
Table Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Regions 2014-2019
Figure Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Regions in 2018
Table Global Secondary Progressive Multiple Sclerosis Drug Consumption by Regions 2014-2019 (K Pcs)
Table Global Secondary Progressive Multiple Sclerosis Drug Consumption Market Share by Regions 2014-2019
Figure North America Secondary Progressive Multiple Sclerosis Drug Production Growth Rate 2014-2019 (K Pcs)
Figure North America Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate 2014-2019 (Million USD)
Table North America Secondary Progressive Multiple Sclerosis Drug Production, Consumption Import and Export (K Pcs)
Figure Europe Secondary Progressive Multiple Sclerosis Drug Production Growth Rate 2014-2019 (K Pcs)
Figure Europe Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate 2014-2019 (Million USD)
Table Europe Secondary Progressive Multiple Sclerosis Drug Production, Consumption Import and Export (K Pcs)
Figure China Secondary Progressive Multiple Sclerosis Drug Production Growth Rate 2014-2019 (K Pcs)
Figure China Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate 2014-2019 (Million USD)
Table China Secondary Progressive Multiple Sclerosis Drug Production, Consumption Import and Export (K Pcs)
Figure Japan Secondary Progressive Multiple Sclerosis Drug Production Growth Rate 2014-2019 (K Pcs)
Figure Japan Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate 2014-2019 (Million USD)
Table Japan Secondary Progressive Multiple Sclerosis Drug Production, Consumption Import and Export (K Pcs)
Figure Southeast Asia Secondary Progressive Multiple Sclerosis Drug Production Growth Rate 2014-2019 (K Pcs)
Figure Southeast Asia Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate 2014-2019 (Million USD)
Table Southeast Asia Secondary Progressive Multiple Sclerosis Drug Production, Consumption Import and Export (K Pcs)
Figure India Secondary Progressive Multiple Sclerosis Drug Production Growth Rate 2014-2019 (K Pcs)
Figure India Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate 2014-2019 (Million USD)
Table India Secondary Progressive Multiple Sclerosis Drug Production, Consumption Import and Export (K Pcs)
Figure Global Consumption Secondary Progressive Multiple Sclerosis Drug Market Share by Application (2014-2019)
Figure Global Value (Consumption) Secondary Progressive Multiple Sclerosis Drug Market Share by Application (2014-2019)
Table AB Science SA Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
Table AB Science SA Secondary Progressive Multiple Sclerosis Drug Product Introduction, Application and Specification
Table AB Science SA Secondary Progressive Multiple Sclerosis Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table AB Science SA Secondary Progressive Multiple Sclerosis Drug Production Growth Rate (2014-2019)
Table AB Science SA Secondary Progressive Multiple Sclerosis Drug Production Market Share (2014-2019)
Figure AB Science SA Secondary Progressive Multiple Sclerosis Drug Revenue Market Share (2014-2019)
Table AB Science SA Secondary Progressive Multiple Sclerosis Drug Main Business and Markets Served
Table Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
Table Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Product Introduction, Application and Specification
Table Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Production Growth Rate (2014-2019)
Table Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Production Market Share (2014-2019)
Figure Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Revenue Market Share (2014-2019)
Table Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Main Business and Markets Served
Table Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
Table Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Product Introduction, Application and Specification
Table Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Production Growth Rate (2014-2019)
Table Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Production Market Share (2014-2019)
Figure Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Revenue Market Share (2014-2019)
Table Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Main Business and Markets Served
Table F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
Table F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Product Introduction, Application and Specification
Table F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Production Growth Rate (2014-2019)
Table F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Production Market Share (2014-2019)
Figure F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Revenue Market Share (2014-2019)
Table F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Main Business and Markets Served
Table Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
Table Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Product Introduction, Application and Specification
Table Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Production Growth Rate (2014-2019)
Table Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Production Market Share (2014-2019)
Figure Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Revenue Market Share (2014-2019)
Table Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Main Business and Markets Served
Table Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
Table Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Product Introduction, Application and Specification
Table Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Production Growth Rate (2014-2019)
Table Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Production Market Share (2014-2019)
Figure Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Revenue Market Share (2014-2019)
Table Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Main Business and Markets Served
Table Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
Table Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Product Introduction, Application and Specification
Table Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Production Growth Rate (2014-2019)
Table Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Production Market Share (2014-2019)
Figure Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Revenue Market Share (2014-2019)
Table Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Main Business and Markets Served
Table Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
Table Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Product Introduction, Application and Specification
Table Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Production Growth Rate (2014-2019)
Table Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Production Market Share (2014-2019)
Figure Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Revenue Market Share (2014-2019)
Table Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Main Business and Markets Served
Table Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
Table Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Product Introduction, Application and Specification
Table Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Production Growth Rate (2014-2019)
Table Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Production Market Share (2014-2019)
Figure Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Revenue Market Share (2014-2019)
Table Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Main Business and Markets Served
Table Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
Table Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Product Introduction, Application and Specification
Table Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Production (K Pcs), Revenue (Million USD), Ex-factory Price (USD/Pcs) and Gross Margin (2014-2019)
Table Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Production Growth Rate (2014-2019)
Table Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Production Market Share (2014-2019)
Figure Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Revenue Market Share (2014-2019)
Table Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Main Business and Markets Served
Table MedDay SA Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
Table MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
Table Merck KGaA Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
Table Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
Table Novartis AG Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
Table Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
Table Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Production Sites and Area Served
Figure Global Secondary Progressive Multiple Sclerosis Drug Production (K Pcs) Growth Rate Forecast 2019-2025
Figure Global Secondary Progressive Multiple Sclerosis Drug Revenue (Million USD) Growth Rate Forecast 2019-2025
Figure Global Secondary Progressive Multiple Sclerosis Drug Sales Price (USD/Pcs) Forecast 2019-2025
Figure North America Secondary Progressive Multiple Sclerosis Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure North America Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Europe Secondary Progressive Multiple Sclerosis Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Europe Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure China Secondary Progressive Multiple Sclerosis Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure China Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Japan Secondary Progressive Multiple Sclerosis Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Japan Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure Southeast Asia Secondary Progressive Multiple Sclerosis Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure Southeast Asia Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Figure India Secondary Progressive Multiple Sclerosis Drug Production Growth Rate Forecast 2019-2025 (K Pcs)
Figure India Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate Forecast 2019-2025 (Million USD)
Table Global Production (K Pcs) of Secondary Progressive Multiple Sclerosis Drug by Type (2019-2025)
Table Global Consumption (K Pcs) of Secondary Progressive Multiple Sclerosis Drug by Application (2019-2025)
Table Secondary Progressive Multiple Sclerosis Drug Distributors List
Table Secondary Progressive Multiple Sclerosis Drug Customers List
Table Market Key Trends
Table Key Opportunities
Table Market Key Drivers
Table Key Challenges
Table Key Influence Factors
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources


【掲載企業】

AB Science SA、Actelion Ltd、Biogen, Inc.、F. Hoffmann-La Roche Ltd.、Genzyme Corporation、Glialogix, Inc.、Immune Response BioPharma, Inc.、Innate Immunotherapeutics Ltd、Kyorin Pharmaceutical Co., Ltd.、Mallinckrodt Plc、MedDay SA、MedImmune, LLC、Merck KGaA、Meta-IQ ApS、Novartis AG、Opexa Therapeutics, Inc.、Xenetic Biosciences (UK) Limited、

★調査レポート[世界の二次性進行性多発性硬化症薬市場 2019年] (コード:DATA909X14808)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の二次性進行性多発性硬化症薬市場 2019年]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆